BIOPOLIS SL

Their core work

Biopolis is a Spanish private biotech SME based in Paterna (Valencia) specializing in applied microbiology, systems biology, and biotechnology services. They develop microbial platforms for industrial applications — from engineering microbial consortia that produce valuable chemicals, to optimizing bioprocesses for food safety, bio-based packaging, and waste valorization. Their core capability lies in translating microbiological research into tangible industrial solutions across the food, environment, and bioeconomy sectors.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Biopolis focused on plant health diagnostics (VirFree), microalgae applications (ALGAE4A-B), and initial bioprocessing work (DAFIA, BIOSEA). From 2019 onward, they shifted decisively toward synthetic biology and microbial engineering (SynBio4Flav, PROMICON), circular bioeconomy (WaysTUP!, PRESERVE), and advanced food chain optimization (ICHTHYS). The trajectory shows a company moving from general applied microbiology toward more sophisticated systems biology and engineered microbial platforms for industrial sustainability.

Biopolis is consolidating around engineered microbial systems for sustainable industrial production — expect future work at the intersection of synthetic biology, waste valorization, and bio-based materials.

How they like to work

Biopolis operates exclusively as a participant or partner — never coordinating — which positions them as a reliable technical contributor that larger consortia invite for specialized microbiology and bioprocessing expertise. With 175 unique partners across 32 countries, they maintain an exceptionally broad network for an SME, suggesting they are well-regarded and frequently sought after. Their involvement in both MSCA mobility actions and large RIA/BBI projects indicates flexibility in adapting to different consortium formats and research cultures.

Biopolis has collaborated with 175 unique partners across 32 countries, an unusually wide network for an SME of their size. Their reach spans all of Europe and beyond, with strong connections through both large industrial consortia (BBI-RIA) and research training networks (MSCA).

What sets them apart

Biopolis sits at a rare intersection: they are a private biotech SME with deep academic-grade expertise in systems biology and microbial engineering, yet oriented toward industrial application. Unlike university labs, they can deliver contract R&D with commercial timelines; unlike large biotech firms, they are agile and accessible for consortium work. Their proven ability to contribute across food, environment, and bioeconomy projects makes them a versatile partner when a consortium needs applied microbiology capabilities without the overhead of a large organization.

Highlights from their portfolio

• WaysTUP!
  Largest single EC contribution (EUR 834K) — transforming urban biowaste into biobased products, demonstrating Biopolis's growing role in circular bioeconomy.
• PROMICON
  EUR 550K for engineering productive microbial consortia — represents their most advanced synthetic biology work and future strategic direction.
• SynBio4Flav
  EUR 615K for building synthetic microbial consortia to produce flavonoids — highlights their core strength in designing functional microbial platforms.